Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan seeks to quell public outrage of its EpiPen Pricing with a generic version of the product.
Publish date:

Mylan  (MYL) - Get Report  has introduced a generic version of its EpiPens after public outrage over its pricing. But TheStreet's Jim Cramer says he's happy the company rolled back prices, but he still isn't a fan of the stock.